Drug Trial Radar · NCT05394116
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
63
Actual
Start
Nov 21, 2022
Primary completion
Jul 17, 2025
Study completion Feb 27, 2029
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- May 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP). The aim of the study is to see how safe and effective the study drug is in patients with FOP. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Fibrodysplasia Ossificans Progressiva
Interventions
GaretosmabDrug
Garetosmab is supplied as a liquid drug product and will be administered IV.
PlaceboDrug
Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of New Heterotopic Ossification (HO) LesionsTime frame: Week 56
- Number of Participants With Treatment-emergent (TE) Adverse Events of Special Interest (AESIs)Time frame: Baseline up to Week 56 [to include participants who discontinued earlier]
Locations
22 sites in 18 countries. Site status is shown where the registry gives one.
University of California Los Angeles (UCLA) Medical Center
Los Angeles, California
Vanderbilt University Medical Center
Nashville, Tennessee
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Hospital Israelita Albert Einstein
São Paulo, Brazil
Universidad de Concepcion
Concepción, Biobio, Chile
Tongji Hospital of Tongji University
Shanghai, China
Clinica Universidad de La Sabana
Chía, Cundinamarca, Colombia
HUS Children and Adolescents Park Hospital Clinical Trial Unit
Helsinki, Stenbäckinkatu 11, Finland
Hôpital Lapeyronie
Montpellier, France
Hopital Lariboisiere
Paris, France
Queen Mary Hospital
Hong Kong, Hong Kong
IRCCS Istituto Giannina Gaslini
Genoa, Italy
Kyushu University Hospital
Fukuoka, Japan
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
Oita University Hospital
Yufu, Oita Prefecture, Japan
Hospital Kuala Lampur
Kuala Lumpur, Malaysia
Amsterdam University Medical Center
Amsterdam, North Holland, Netherlands
Szpital Centrum Medyczne Medyk
Rzeszów, Podkarpackie Voivodeship, Poland
University of Cape Town
Rondebosch, Cape Town, South Africa
Seoul National University Hospital
Seoul, South Korea
Hospital Universitario Ramon y Cajal
Madrid, Spain
Royal National Orthropaedic Hospital NHS Trust
Middlesex, Greater London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.